Recent developments
Capacity expands globally
CDMO capacity expanded across regions. WuXi Biologics moved into the Middle East via a strategic MoU with the Qatar Free Zones Authority to establish a CRDMO center. Terumo Corporation acquired a WuXi Biologics drug-product site in Leverkusen, adding fill‑finish. Merck began construction of a $3 billion pharmaceutical facility in Virginia. BBG Advanced Therapies and CELLforCURE formed a transatlantic ATMP manufacturing partnership.
Drug delivery advances
Drug delivery platforms advanced. Evonik unveiled GMP-grade EUDRACAP colon capsules at CPHI Frankfurt for ileo‑colonic targeting, recognized with the CPHI Excellence in Pharma Award. Evonik and Ethris initiated a collaboration on a lipid nanoparticle platform for nucleic acid delivery, including thermostable formats. Evonik also launched MaxiPure Polysorbate 80 to tighten excipient quality for injectables.
Modalities and processes
Modality supply chains and processes evolved. Mitsubishi Gas Chemical and Cirena moved toward exclusive distribution of long‑chain RNA in Japan, aligning with nucleic acid CDMO strategies. Evonik introduced the Noblyst F catalysts for flow applications, supporting the shift to continuous processing in pharma and fine chemicals.
Quality and ESG
Quality and ESG benchmarks featured prominently. WuXi Biologics received TITCK GMP certifications for three manufacturing facilities in Wuxi. The company was included in the Hang Seng Corporate Sustainability Benchmark and retained an MSCI AAA ESG rating. Frost & Sullivan recognized customer value leadership for WuXi Biologics’ CRDMO model.
Market and ecosystem
Market signals and ecosystem support continued. Merck announced Q3 2025 financial results showing 4% year‑over‑year sales growth. WACKER’s Q2 2025 earnings reflected lower volumes and utilization. Eli Lilly expanded its Gateway Labs network to Philadelphia to support early‑stage biotech collaboration.